Gilead's deal of a lifetime.
Gilead Sciences' ascent to the upper echelon of biotech centered around one very savvy acquisition that launched an HIV franchise.
Brady
B
Huggett
Christopher
C
Scott
D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000191:economics*; D004345:Drug Industry / Q000191:economics*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy
D019380:Anti-HIV Agents